Are you a journalist? Please sign up here for our press releases
Weizmann Institute scientists have developed a research platform for designing tiny antibodies that can halt the virus infection process
A new method of redesigning protein molecules may yield novel drugs.
Dr. Sarel-Jacob Fleishman is the recipient of the Human Frontier Science Program (HFSP) Career Development Award (2012)